Abstract: Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with a pharmaceutical carrier, excipient, or diluent. The compositions are suitable as vaccines for treating or preventing drusen and diseases associated with drusen.

Abstract: Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with a pharmaceutical carrier, excipient, or diluent. The compositions are suitable as vaccines for treating or preventing drusen and diseases associated with drusen.

Abstract: Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with a pharmaceutical carrier, excipient, or diluent. The compositions are suitable as vaccines for treating or preventing drusen and diseases associated with drusen.

Abstract: Therapeutic methods and compositions for the treatment of glaucoma and other conditions mediated at least in part by the expression of NOS-2 are provided.

Abstract: This invention is directed to treatment for increasing the accommodative ability of the eye, for the purpose of decreasing the severity of clinically evident presbyopia, an age-related loss of accommodative ability. The compounds and methods of the invention act by decreasing the tone of parts of the ciliary muscle which act to decrease accommodation, thereby increasing the contractile force of the remaining ciliary muscle, with resultant increased accommodative function.

Abstract: This invention is directed to treatment for increasing the accommodative ability of the eye, for the purpose of decreasing the severity of clinically evident presbyopia, an age-related loss of accommodative ability. The compounds and methods of the invention act by decreasing the tone of parts of the ciliary muscle which act to decrease accommodation, thereby increasing the contractile force of the remaining ciliary muscle, with resultant increased accommodative function.

Abstract: The composition and method of using a non-steroidal antiinflammatory compound, such as indomethacin and/or a growth factor that causes a change in cell function when bound to specific cell surface receptor, such as epidermal growth factor (EGF), to enhance healing and restore function of the corneal endothelium. The compositions can be administered alone, in combination, or in sequence, before or after injury, for example, in an irrigation solution or in combination with a nutritive solution for storage of cornea prior to transplant.

Abstract: Method using a non-steroidal antiinflammatory compound, such as indomethacin and/or a growth factor that causes a change in cell function when bound to a specific cell surface receptor, such as epidermal growth factor (EGF), to enhance healing and restore function of the corneal endothelium. The compositions can be adminsitered alone, in combination, or in sequence, before or after injury, for example, in an irrigation solution or in combination with a nutritive solution for storage of a cornea prior to transplant.Examples of useful growth factors include, in addition to EGF and EGF-like compounds, fragments of EGF containing the receptor binding region, and EGF modified to improve stability, increase half-life, or enhance permeation into the eye. Examples of other non-steroidal antiinflammatories include aspirin, ibuprofen, and suprofen. The composition can be applied topically to the eye or delivered in a controlled fashion by means of a material such as a polymeric implant, gel, or liposomes.

Abstract: Method using a non-steroidal antiinflammatory compound, such as indomethacin and/or a growth factor that causes a change in cell function when bound to a specific cell surface receptor, such as epidermal growth factor (EGF), to enhance healing and restore function of the corneal endothelium. The compositions can be administered alone, in combination, or in sequence, before or after injury, for example, in an irrigation solution or in combination with a nutritive solution for storage of a cornea prior to transplant.Examples of useful growth factors include, in addition to EGF and EGF-like compounds, fragments of EGF containing the receptor binding region, and EGF modified to improve stability, increase half-life, or enhance permeation into the eye. Examples of other non-steroidal antiinflammatories include aspirin, ibuprofen, and suprofen. The composition can be applied topically to the eye or delivered in a controlled fashion by means of a material such as a polymeric implant, gel, or liposomes.

Abstract: An in vitro testing method for biocompatibility, particularly toxicological effect, of substances is based on the change in the time for closure of a disruption in a confluent cell culture caused by treatment with the substance. The method can be used to replace a substantial number of toxicity tests, including the Draize test for ocular irritancy.